Novartis buys stem cell technology from Opexa Therapeutics

08/9/2009 | Reuters

Novartis purchased Opexa Therapeutics' preclinical-stage stem cell technology in a deal that could be worth more than $50 million. The sale allows Opexa to concentrate on the development and commercialization of multiple sclerosis drug Tovaxin, which is in midstage studies.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD